Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shandong Fontacea In-Licenses IL-17A Candidate from Janssen

publication date: Dec 18, 2019

Shandong Fontacea Pharma in-licensed greater China rights to a human IgG1λ anti-human IL-17A neutralizing mAb from Janssen Biotech. Further details of the candidate were not disclosed, although it is known Janssen has several interleukin mAbs in development or approved for autoimmune diseases with a focus on psoriasis diseases. Fontacea, a novel drug discovery biopharma located in the Jining Hightech Zone, is developing medicines for patients with respiratory diseases, inflammatory/autoimmune diseases and cancer. The companies did not comment on the financial details of the agreement. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital